Recombinant Phoneutria nigriventer Tachykinin-like peptide-IV

What are the primary characteristics of tachykinin-like peptides in Phoneutria nigriventer venom?

Tachykinin-like peptides from P. nigriventer belong to a family of short linear peptides (LPs) found in the PhTx5 group of venom components. Unlike the cysteine-rich neurotoxins that make up PhTx1-4 groups, these peptides lack disulfide bridges and typically present α-helical motifs when interacting with membrane structures. They have been detected in comprehensive venom analyses, with complex precursor structures encoding these peptides identified through transcriptomic approaches. Structural diversity among these peptides is extraordinarily high in certain spider species, including P. nigriventer, making them valuable subjects for neuropharmacological research .

The primary sequence analysis of these peptides reveals characteristic features that distinguish them from other venom components, with specific amino acid patterns that contribute to their biological activity. Their hydrophilicity profiles and molecular weights differ from the more abundant cysteine-rich neurotoxins that target voltage-gated ion channels in the venom.

What neurophysiological targets are affected by P. nigriventer tachykinin-like peptides?

P. nigriventer tachykinin-like peptides interact with multiple neuronal targets, contributing to the complex pharmacological profile of the whole venom. Research shows these peptides may influence serotonergic pathways, as the venom contains quantifiable amounts of serotonin that can be detected through spectrofluorophotometric methods . The peptides likely interact with G-protein coupled receptors, including 5-HT4 receptors identified in studies of nociception mechanisms triggered by the venom .

Unlike the voltage-gated ion channel modulators that comprise the majority of the venom's neurotoxic components, tachykinin-like peptides may participate in pain signaling through indirect mechanisms. This is evident from studies showing that P. nigriventer venom activates multiple nociceptive pathways, including those mediated by acid-sensitive ion channels (ASIC) and transient receptor potential vanilloid 1 (TRPV1) receptors .

How do tachykinin-like peptides differ from other peptide classes in the venom?

Tachykinin-like peptides represent a distinct class among P. nigriventer venom components. While cysteine-rich peptides in groups PhTx1-4 directly modulate voltage-gated calcium (CaV), sodium (NaV), and potassium (KV) channels, tachykinin-like peptides generally lack the complex disulfide bonding pattern that characterizes these other toxins .

Structurally, P. nigriventer venom peptides can be classified into several groups:

• μ-toxins and ω-toxins (Group 1) - more hydrophilic peptides that modulate sodium and calcium channels

• κ-peptides (Group 2) - moderately hydrophobic peptides affecting potassium channels

• γ-peptides (Group 3) - more hydrophobic peptides typically modulating non-specific cation channels

• Linear peptides including tachykinin-like peptides (Group 5) - lacking disulfide bridges and often exhibiting membrane interactions

This structural diversity reflects functional specialization, with tachykinin-like peptides potentially playing roles in pain induction and inflammatory response rather than direct neurotoxicity observed with other venom components.

What are the challenges in recombinant expression of P. nigriventer tachykinin-like peptide-IV?

Recombinant production of P. nigriventer tachykinin-like peptide-IV presents several specific challenges. Unlike cysteine-rich venom peptides that require precise disulfide bond formation, the challenges with linear tachykinin-like peptides center around maintaining proper secondary structure formation and preventing aggregation during expression.

Researchers have noted that modern strategies utilizing high-throughput recombinant expression systems must be adapted for these particular peptides . Common challenges include:

• Selecting appropriate expression vectors that account for the peptide's relatively small size

• Optimizing codon usage for the expression host (typically E. coli or yeast systems)

• Determining optimal fusion partners to enhance solubility and prevent degradation

• Developing purification strategies that maintain bioactivity while achieving high purity

• Confirming proper folding of the recombinant peptide compared to the native form

The field has benefited from advanced recombinant techniques, with researchers noting that "modern strategies utilizing HT recombinant expression or chemical synthesis" are essential for further exploration of these peptides . Post-translational modifications present in native peptides must also be considered when designing recombinant expression strategies.

How do structural characteristics of recombinant tachykinin-like peptide-IV influence its pharmacological properties?

The structural characteristics of recombinant tachykinin-like peptide-IV significantly influence its pharmacological activity through several mechanisms. Unlike the cysteine-rich peptides that maintain rigid structures through disulfide bridges, tachykinin-like peptides adopt their bioactive conformations through secondary structural elements when interacting with targets.

Research with other P. nigriventer peptides demonstrates how structural engineering can dramatically affect bioactivity. For example, the engineered peptide PnPP-19 was designed based on the theoretical structure of PnTx2-6 toxin by selecting the most exposed region as its probable interaction site with sodium channels . Similar principles may apply to tachykinin-like peptides.

Key structural features affecting pharmacological properties include:

• The potential α-helical motifs that form upon target binding

• The distribution of charged residues that may create "KR trap" pharmacophores similar to those identified in other P. nigriventer peptides

• N-terminal and C-terminal modifications that enhance stability (carboxylation at N-terminal and amidation at C-terminal)

• Hydrophobic/hydrophilic balance affecting target selectivity and membrane interactions

Understanding these structure-activity relationships is essential for rational design of peptide variants with enhanced therapeutic potential while minimizing toxicity.

What experimental models are most appropriate for evaluating recombinant tachykinin-like peptide-IV bioactivity?

Selecting appropriate experimental models for evaluating the bioactivity of recombinant tachykinin-like peptide-IV requires careful consideration of the peptide's putative mechanisms and target systems. Based on research with P. nigriventer venom components, several model systems have proven valuable:

• Neuroblastoma cell lines: High-throughput cellular assays using neuroblastoma cells allow for rapid screening of peptide activity on multiple neuronal ion channels . These have been successfully coupled with proteomics to identify bioactive fractions in the venom.

• Pain models in rodents: Given the involvement of P. nigriventer venom in nociception, rodent models evaluating mechanical and thermal hyperalgesia have been employed. These models have revealed that venom components act through kinin B2, TRPV1, 5-HT4, and ASIC receptors .

• Electrophysiological assays: Automated whole-cell patch-clamp electrophysiology provides detailed functional data on peptide interactions with specific ion channels and receptors .

• Disease-specific models: Based on therapeutic applications already identified for P. nigriventer peptides, models for erectile dysfunction, glaucoma, Huntington's disease, and chronic pain represent relevant systems for evaluating novel tachykinin-like peptides .

The integration of these models into a systematic evaluation pipeline enables comprehensive characterization of recombinant peptides from initial screening to detailed mechanistic studies.

What purification strategy yields optimal results for recombinant P. nigriventer tachykinin-like peptide-IV?

A multi-step purification strategy optimized for linear peptides yields the best results when working with recombinant P. nigriventer tachykinin-like peptide-IV. Based on approaches used for other spider venom peptides, an effective purification workflow includes:

• Initial clarification: After cell lysis, centrifugation at 16,000× g at 4°C for 60 minutes effectively separates soluble peptides from cellular debris .

• Affinity chromatography: If expressed with affinity tags (His, GST, or MBP), appropriate affinity columns can capture the fusion protein. Tag removal must be followed by additional purification steps.

• Reversed-phase HPLC: Critical for achieving high purity, RP-HPLC separation on C18 columns with acetonitrile gradients effectively separates tachykinin-like peptides based on hydrophobicity. The retention time pattern provides valuable information about peptide properties, as demonstrated in comprehensive venom profiling studies .

• Size-exclusion chromatography: A final polishing step to remove any aggregates or differently folded species.

• Quality control: Mass spectrometry (particularly MALDI-TOF and ESI-MS) should be employed to confirm peptide identity and purity, with circular dichroism spectroscopy to verify secondary structure formation.

Researchers should monitor bioactivity throughout the purification process, as some methods may affect the peptide's functional properties. The use of protease inhibitors during early purification stages is recommended to prevent degradation.

How can researchers effectively evaluate the receptor selectivity of recombinant tachykinin-like peptide-IV?

Evaluating receptor selectivity of recombinant tachykinin-like peptide-IV requires a systematic approach integrating multiple complementary methods:

• Competitive binding assays: Using radiolabeled or fluorescently labeled known ligands of tachykinin receptors to measure displacement by the recombinant peptide. This approach establishes binding affinity (Ki values) for different receptor subtypes.

• Calcium mobilization assays: Since tachykinin receptor activation typically triggers calcium signaling, fluorescent calcium indicators in receptor-expressing cell lines provide functional readouts of receptor activation and selectivity.

• High-throughput cellular screens: Similar to approaches used for whole venom characterization, automated cellular screens against multiple ion channels and receptors can efficiently map the pharmacological profile of the recombinant peptide .

• Receptor knockout models: Testing the peptide in systems where specific receptors have been genetically deleted can confirm target specificity in more complex biological systems.

• Structure-activity relationship studies: Systematic modification of specific amino acid residues can identify the pharmacophore and determine which structural elements confer selectivity for particular receptor subtypes.

This multi-faceted approach provides comprehensive characterization of receptor selectivity profiles, essential for understanding the peptide's mechanism of action and therapeutic potential.

What analytical methods should be used to confirm the structural integrity of recombinant tachykinin-like peptide-IV?

Confirming the structural integrity of recombinant tachykinin-like peptide-IV requires multiple complementary analytical techniques:

• Mass spectrometry:

  • Electrospray ionization mass spectrometry (ESI-MS) for accurate molecular weight determination

  • MALDI-TOF MS for peptide fingerprinting

  • Tandem MS (MS/MS) for sequence confirmation and identification of post-translational modifications

• Spectroscopic methods:

  • Circular dichroism (CD) spectroscopy to assess secondary structure elements, particularly important for confirming α-helical motifs that may be critical for bioactivity

  • Fluorescence spectroscopy to evaluate tertiary structure and conformational states

  • Nuclear magnetic resonance (NMR) for detailed structural characterization in solution

• Chromatographic analysis:

  • Analytical reversed-phase HPLC to confirm purity and retention behavior

  • Size-exclusion chromatography to detect aggregation states

• Functional assays:

  • Bioactivity assays compared to synthetic or native peptide standards

  • Stability tests under various pH and temperature conditions

The combination of these methods provides comprehensive structural verification, ensuring that the recombinant peptide accurately represents the native peptide in terms of both primary sequence and higher-order structure.

What are the key considerations for designing recombinant expression constructs for P. nigriventer tachykinin-like peptide-IV?

Designing effective expression constructs for P. nigriventer tachykinin-like peptide-IV requires careful consideration of several factors:

• Vector selection: Expression vectors with strong, inducible promoters (T7, tac) are generally preferred. For small peptides like tachykinin-like peptide-IV, vectors supporting high copy numbers can enhance yield.

• Fusion partners: Fusion proteins significantly impact expression success. Consider:

  • Solubility enhancers (SUMO, MBP, Thioredoxin)

  • Affinity tags for purification (His6, GST)

  • Cleavage sites for tag removal (TEV protease, Factor Xa, enterokinase)

• Codon optimization: Adapting the coding sequence to the expression host's codon bias improves translation efficiency, especially important for peptides with rare codons.

• Signal sequences: For secreted expression, appropriate signal peptides direct the recombinant peptide to the secretory pathway, potentially improving folding and reducing toxicity to the host.

• Terminal modifications: Consider incorporating modifications found in the native peptide:

  • C-terminal amidation

  • N-terminal modifications

  • Strategic amino acid substitutions to enhance stability or prevent aggregation, similar to the Cys-to-Ser substitution employed in the engineering of PnPP-19

• Expression host compatibility: While E. coli remains the most common host, yeast or insect cell systems may provide advantages for certain peptides, particularly if post-translational modifications are required.

The design should be informed by the principles successfully applied to other P. nigriventer peptides, while accounting for the specific characteristics of tachykinin-like peptide-IV.

How can recombinant P. nigriventer tachykinin-like peptide-IV contribute to pain research?

Recombinant P. nigriventer tachykinin-like peptide-IV offers significant potential for advancing pain research through several mechanisms:

• Novel pain pathway investigation: The peptide can serve as a molecular probe to investigate specific nociceptive pathways. P. nigriventer venom components have already been shown to interact with key pain-mediating receptors including TRPV1, ASIC channels, and serotonin receptors . Recombinant tachykinin-like peptide-IV could help dissect the specific contributions of each pathway.

• Therapeutic lead development: Other P. nigriventer peptides have demonstrated antinociceptive properties in rodent models . Recombinant tachykinin-like peptide-IV could be systematically modified based on structure-activity relationships to develop novel analgesic compounds with potentially fewer side effects than current treatments.

• Understanding inflammatory pain: The interaction between tachykinin-like peptides and inflammatory mediators, including the kallikrein-kinin system identified in whole venom studies , provides insights into inflammatory pain mechanisms. Recombinant peptides allow controlled investigation of these interactions.

• Development of selective receptor modulators: By understanding the precise receptor interactions of tachykinin-like peptide-IV, researchers can develop selective modulators of pain-relevant receptors, potentially leading to novel analgesic drugs with improved side effect profiles.

Researchers have already demonstrated that P. nigriventer venom contains peptides with therapeutic effects in chronic pain models , suggesting that individual components like tachykinin-like peptide-IV warrant further investigation as both research tools and therapeutic leads.

What experimental design considerations are critical when evaluating potential therapeutic applications of recombinant tachykinin-like peptide-IV?

When evaluating potential therapeutic applications of recombinant tachykinin-like peptide-IV, several critical experimental design considerations must be addressed:

• Dosage determination and pharmacokinetics:

  • Establish dose-response relationships across multiple concentrations

  • Determine half-life and biodistribution in relevant models

  • Evaluate different administration routes (local vs. systemic)

• Target validation:

  • Confirm receptor specificity through knockout models or selective antagonists

  • Validate the relevance of the target to the disease pathway

  • Assess potential off-target effects through broad screening approaches

• Comparative effectiveness:

  • Include appropriate positive controls (existing therapies)

  • Design experiments to detect advantages over current treatments

  • Consider combination approaches with established therapies

• Model selection:

  • Choose disease models that best represent human pathophysiology

  • Use multiple models to confirm efficacy (e.g., different pain models for analgesic applications)

  • Include both acute and chronic administration protocols to assess tolerance development

• Safety assessment:

  • Screen for immunogenicity of the recombinant peptide

  • Evaluate potential toxicity at therapeutic doses and above

  • Assess impact on physiological parameters beyond the target system

These considerations should be structured within a systematic evaluation pipeline that progresses from in vitro characterization through appropriate animal models before considering clinical applications, following the successful development pathway established for other P. nigriventer peptides like PnPP-19 .

How do structural modifications affect the stability and bioavailability of recombinant tachykinin-like peptide-IV?

Structural modifications significantly impact the stability and bioavailability of recombinant tachykinin-like peptide-IV, offering opportunities to optimize these properties for research and therapeutic applications:

• Terminal modifications: Similar to strategies applied to PnPP-19, carboxylation at the N-terminal and amidation at the C-terminal can provide higher stability to the molecule . These modifications protect against exopeptidase degradation, potentially extending in vivo half-life.

• Strategic amino acid substitutions: Substituting certain amino acids can enhance stability without compromising activity. For example, the replacement of Cys with Ser in PnPP-19 maintained function while improving stability . Similar rational substitutions could be applied to tachykinin-like peptide-IV based on structure-activity relationship studies.

• Cyclization strategies: While natural tachykinin-like peptides are linear, introducing artificial cyclization through various chemistries (lactam bridges, click chemistry, etc.) can significantly enhance proteolytic stability.

• Pegylation and other conjugations: Attaching polyethylene glycol (PEG) or other moieties to the peptide can dramatically improve pharmacokinetic properties, though care must be taken to preserve activity at the target site.

• Formulation approaches:

  • Lipid nanoparticles for enhanced delivery across biological barriers

  • Controlled-release formulations to maintain therapeutic concentrations

  • Site-specific delivery systems to reduce systemic exposure

Each modification strategy requires systematic evaluation of its impact on both stability and biological activity, as structural changes that enhance stability may sometimes compromise the precise conformational requirements for receptor binding and activation.

How does tachykinin-like peptide-IV compare structurally and functionally to mammalian tachykinins?

Tachykinin-like peptide-IV from P. nigriventer shows both similarities and important differences when compared to mammalian tachykinins:

• Sequence homology: While P. nigriventer tachykinin-like peptides share some sequence motifs with mammalian tachykinins, they represent distinct evolutionary lineages. Both typically contain a high proportion of basic and hydrophobic residues, but the specific patterns differ, reflecting their divergent evolutionary origins.

• Receptor interactions: Mammalian tachykinins (substance P, neurokinin A, neurokinin B) primarily activate neurokinin receptors (NK1, NK2, NK3). P. nigriventer tachykinin-like peptides may interact with these receptors but often with different selectivity profiles and potentially through distinct binding modes. They may also target additional receptors not typically associated with mammalian tachykinins .

• Structural properties: Both classes adopt α-helical conformations when interacting with their targets , but spider tachykinin-like peptides may have unique structural features that contribute to their specific activity profiles and stability in venom.

• Biological roles: Mammalian tachykinins function as neurotransmitters and neuromodulators in pain transmission, inflammation, and smooth muscle contraction. P. nigriventer tachykinin-like peptides evolved as venom components for prey capture and defense, potentially explaining their distinct pharmacological properties.

Understanding these comparative aspects not only illuminates evolutionary biology but also guides the development of selective peptide-based tools for manipulating specific tachykinin-related signaling pathways.

What can we learn about peptide evolution from studying recombinant tachykinin-like peptide-IV?

Studying recombinant tachykinin-like peptide-IV provides valuable insights into peptide evolution through several perspectives:

• Convergent evolution: The presence of tachykinin-like peptides in spider venom represents an example of molecular convergence, where similar functional roles are fulfilled by peptides that evolved independently. Comparative studies between recombinant tachykinin-like peptide-IV and mammalian tachykinins can reveal how different evolutionary pathways arrived at similar functional solutions.

• Accelerated evolution in venom peptides: Venom peptides typically evolve under strong positive selection pressure, resulting in high sequence diversity. Tachykinin-like peptides from P. nigriventer demonstrate this principle, with complex precursor structures encoding diverse peptide variants . Recombinant expression allows systematic exploration of this diversity.

• Structure-function relationships across evolutionary distance: By expressing recombinant variants based on sequences from different spider species, researchers can map how structural changes correlate with functional diversification across evolutionary time.

• Precursor organization and processing: The study of recombinant expression constructs mimicking natural precursors provides insights into how peptide families evolve through mechanisms like gene duplication and sequence divergence. The complex precursor structures encoding short linear peptides identified in P. nigriventer and related species reveal evolutionary strategies for generating peptide diversity .

These evolutionary insights not only contribute to fundamental biology but also inform biomimetic approaches to peptide drug development based on nature's solutions to biological targeting challenges.

What are the most promising future research directions for recombinant P. nigriventer tachykinin-like peptide-IV?

The study of recombinant P. nigriventer tachykinin-like peptide-IV presents several promising research frontiers with significant potential impact:

• Therapeutic development pipeline: Following the successful example of PnPP-19, which has shown efficacy in models of erectile dysfunction, pain, and glaucoma , recombinant tachykinin-like peptide-IV could be systematically evaluated across disease models where tachykinin signaling plays a role. This includes chronic pain, neuroinflammatory conditions, and potentially neurodegenerative disorders.

• Advanced structural biology approaches: Applying techniques like cryo-electron microscopy and X-ray crystallography to complexes of the recombinant peptide with its target receptors would provide unprecedented structural insights into peptide-receptor interactions, enabling structure-based drug design.

• Multimodal targeting strategies: Investigating how tachykinin-like peptide-IV interacts with other venom components could reveal synergistic mechanisms that might be exploited therapeutically. The holistic profiling approach demonstrated for whole venom could be adapted to study such interactions.

• Bioengineering applications: The principles used to engineer PnPP-19 from PnTx2-6 could be applied to tachykinin-like peptide-IV, potentially yielding novel peptides with enhanced therapeutic properties and reduced toxicity.

• Expanded recombinant expression technologies: Developing high-throughput expression systems for spider venom peptides would accelerate research across the field, as noted in recent studies highlighting the challenges and importance of such technologies .